As a Data Scientist at Pra Health Sciences, you are positioned at the intersection of advanced analytics and life-saving clinical research. Your work directly influences how clinical trials are conducted, how patient outcomes are analyzed, and how healthcare data is transformed into actionable intelligence for global life science manufacturers, payers, and providers. You are not just building models; you are solving complex, high-stakes problems that help get the right drugs to the right patients at the right time.
This role requires a blend of rigorous technical expertise and a deep appreciation for the clinical domain. Whether you are working on Real-World Evidence (RWE), Revenue Cycle Management (RCM), or patient journey modeling, your contributions will drive strategic decision-making. You will collaborate with cross-functional teams, including medical experts and clinical operations, to translate intricate business needs into sophisticated analytical solutions. It is a role that demands both intellectual curiosity and the ability to communicate complex findings to stakeholders who may not have a technical background.
Recruiter Screen
reportedMost candidates lose this call inside the first two minutes, during the walkthrough of their own background. The account runs chronologically, sits at the level of tools and titles, and never arrives at a decision anyone could have disagreed with. Anchor on a problem instead of a timeline: what the team could not answer, what you did about it, what happened next. Ninety seconds is enough, and stopping on time leaves room for the half of the call that belongs to you. What you ask about how work gets prioritised signals your level more reliably than the walkthrough does.
What to demonstrate
- Whether your background summary has a shape (problem, decision, consequence) or is a chronological list of tools and employers
- Whether you can account for gaps, short stints and the reason you are looking, unprompted and without hedging
- The substance of the questions you ask back, which an experienced screener reads as a level signal
How to prepare
- Time your opening walkthrough against a clock. If it runs past two minutes, compress the earliest role into a single clause and spend the recovered time on the most recent one
- Write one honest sentence for every gap or short stint visible on your resume and offer it before being asked about it
- Prepare questions about how work arrives and gets prioritised: who writes the request, how often priorities change, and what happens to an analysis after it is delivered
Internal Team Conversations
reportedAn extra round usually exists because something is still open after the standard loop: a skill the earlier interviews did not sample, a level decision, or two interviewers who disagreed. It is rarely a rerun of what you already did well. Ask the recruiter who you are meeting, what function they sit in, and how long the session runs. That is an ordinary scheduling question, and the answer changes what you should prepare. What separates a strong candidate here is treating the round as a fresh evaluation with its own bar, rather than assuming earlier performance carries you through or sinks you.
What to demonstrate
- Whether you can answer well on ground the earlier rounds did not cover, without leaning on what you already said to someone else
- Consistency of the facts in your stories: the same sample size, timeframe, team size and scope of your own role as in earlier conversations
- How you handle an unfamiliar format live, including whether you ask what kind of answer is wanted before producing one
How to prepare
- Ask the recruiter for the interviewer's function, the length, and whether to expect a coding surface, a discussion, or a presentation. Preparing for a 30 minute conversation with a partner team is not the same work as preparing for a 60 minute technical block.
- Write out what each earlier round actually covered, then list the two or three areas nobody probed. That gap is the most likely subject of the extra round.
- Re-read the numbers in the project stories you have already told, so a second telling does not quietly contradict the first.
Technical Assessment
reportedA handful of shapes account for most of what gets asked in this format: a ranking or deduplication inside groups, a running or rolling total, a period-over-period comparison, and a cohort tracked forward over time. Recognising the shape quickly is most of the speed here; deriving it from scratch while a clock runs is where the time goes. Know that a window function keeps every row while a GROUP BY collapses them, and know which one the question needs. If the exercise is in Python instead of SQL, the same shapes arrive as groupby with transform, shift and merge, and the same grain mistakes are available.
What to demonstrate
- Whether you reach the right construct without a detour, such as ROW_NUMBER over a partition to deduplicate instead of a self-join against a MAX subquery
- Whether you know what your window frame actually is, since adding ORDER BY inside OVER changes the default frame and silently changes a running total
- Whether the thing runs. A near-miss that throws an error scores below a plainer query that returns the right rows.
How to prepare
- Write each of the four shapes once from memory against a small schema and keep the working version somewhere you will reread it: dedupe with ROW_NUMBER, a running total, a month-over-month change with LAG, and a retention table
- Compute one running total twice on data with tied timestamps, once on the default frame and once with ROWS BETWEEN UNBOUNDED PRECEDING AND CURRENT ROW, and look at where the two disagree
- If Python is on the table, rebuild the dedupe and the running total with groupby and cumsum, then assert the two implementations return identical rows
Feedback and Offer
reportedAn added round often puts you in front of someone outside the core hiring team: a partner engineer, a product owner, a domain expert, sometimes a more senior manager. The question they are really asking is not whether you can do the work but whether they would trust a number that came from you. That changes what a good answer looks like. Lead with what the decision cost and what it changed, keep the method available but not central, and be plain about the limits of your evidence. Overstating a result is the fastest way to lose this round.
What to demonstrate
- Whether you can explain a technical choice to someone who will never read your code, without either flattening it into nothing or hiding inside jargon
- Honesty about evidence strength: what the analysis establishes, what it only suggests, and what it cannot say at all
- How you take disagreement, specifically whether you update on a good objection, hold your position with reasons, or fold on contact
How to prepare
- Write the two-sentence version of your most technical project for a non-specialist, then check that neither sentence needs a method name to make sense.
- For one result you are proud of, write the strongest objection someone could raise and a response that concedes the part of it that is correct.
- Prepare one decision that turned out to be wrong: how you found out, what it cost, and what you changed afterwards. A senior cross-functional interviewer asks for this more often than a technical one does.
PracHub editorial advice for the preparation topics above.
Ignoring clustering by provider, facility, or site
Patients within a provider panel, and subjects within a trial site, are correlated on both case mix and practice pattern. Standard errors computed as if observations were independent are too narrow by roughly the design effect, 1 + (m - 1) * ICC, where m is the average cluster size. With 50 patients per provider and an intracluster correlation of only 0.02, variance is understated by about a factor of two, which manufactures significant provider differences out of noise. Cluster-robust errors or a random intercept per provider, and cluster-level randomisation when you design the test, are the corrections.
Pre-post evaluation on a high-cost or high-risk cohort
Cohorts selected on an extreme value of the outcome regress toward the mean on their own. Members identified as the top 1 percent of spend in one year spend far less the next, whether or not anyone intervenes, because the selecting year captured both chronic severity and one-off events. A pre-post design on such a cohort will report savings every time. A concurrent comparison group selected by the same rule in the same period, or a regression discontinuity at the selection threshold, is the minimum credible design.
Defining the cohort on a post-treatment condition
Ask how rows entered the table. Filtering on something that treatment itself influences, such as users who finished onboarding or accounts still active at ninety days, breaks comparability between arms; define the population at an entry point that precedes exposure and keep everyone in it.
Answering a product-sense question with a list of features
Answer with a decision and the measurement that would settle it: the hypothesis, the primary metric, the guardrails, and the result that would make you not ship. A feature brainstorm cannot be wrong, which is exactly why it earns no points.
Choose a category, try a prompt, then open its approach, worked solution or follow-up when you need it.
If a model is underperforming in a production environment, what steps …
If a model is underperforming in a production environment, what steps do you take to diagnose and fix the issue?
Approach
- Pick an evaluation metric that matches the cost of each error type, not a default.
- Say how the offline result would be validated online before it is trusted.
- Frame the prediction: the label, the moment of prediction, and the action it triggers.
Follow-up
- Where could label leakage enter this setup?
- What would you monitor after launch to know the model is still valid?
How do you validate the accuracy of a model when working with sensitiv…
How do you validate the accuracy of a model when working with sensitive patient data?
Approach
- Say how the offline result would be validated online before it is trusted.
- Set a baseline first, so any model has something honest to beat.
- Frame the prediction: the label, the moment of prediction, and the action it triggers.
Follow-up
- Where could label leakage enter this setup?
- How would you choose the decision threshold, and who owns that choice?
Simulate how ignoring clustering inflates the false positive rate
Simulate a provider-level comparison with no true effect. 40 providers, 60 members each, a continuous outcome with total variance 1 and intraclass correlation 0.02. Randomise providers 20 to 20, not members. Over 5,000 replications, report the share of replications where a two-sample t-test run on all 2,400 individual observations, ignoring provider, returns p below 0.05. Report the same share when the unit of analysis is the 40 provider means. Then state how the first number follows from the design effect 1 + (m - 1) x ICC.
Approach
- Decompose the variance explicitly rather than tuning it: provider variance = ICC = 0.02, residual variance = 1 - ICC = 0.98. Draw u_j once per provider and e_ij per member, so the outcome is u_j + e_ij and the correlation between two members of one provider is 0.02 by construction.
- Randomise at the provider level. That is the entire mechanism: the treatment indicator is constant within a provider, so in any single replicate the provider intercepts are confounded with the arm, and the naive test reads that confounding as signal.
- Vectorise over replications with a (reps, providers, members) array. 5,000 x 2,400 normals is trivial in numpy, and a Python loop is what tempts people to cut replications to 500 and report a number with Monte Carlo noise of plus or minus 0.017.
- Predict the answer before running it: design effect = 1 + (60 - 1) x 0.02 = 2.18, naive standard errors are too small by sqrt(2.18) = 1.476, so the rejection rate at nominal 0.05 is about 2 x (1 - Phi(1.96 / 1.476)) = 0.18. Agreement between prediction and simulation is what makes the result a demonstration rather than an anecdote.
- Run the provider-mean analysis as the control. Recovering 0.05 there proves the generator is correct and isolates the failure to the analysis unit.
Worked solution 30 min
- Draw u with shape (reps, 40) from N(0, sqrt(0.02)) and e with shape (reps, 40, 60) from N(0, sqrt(0.98)); y = u[:, :, None] + e.
- Assign providers 0-19 to one arm and 20-39 to the other; because there is no true effect, a fixed split is valid and removes one source of Monte Carlo noise.
- Naive test: flatten each arm to 1,200 observations and compute a two-sample t statistic per replication with vectorised means and pooled variance.
- Cluster test: average within provider to 40 values, then run the same two-sample t on 20 versus 20.
- Report both rejection shares and compare the naive one against 2 x (1 - Phi(1.96 / sqrt(2.18))).
Follow-up
- How many providers would you need for 80 percent power on a 0.2 SD difference with 60 members each and this ICC?
- Cluster sizes are unequal in reality. The design effect approximation becomes 1 + ((1 + CV^2) x mbar - 1) x ICC. Which direction does that move your sample size and why?
- The intervention cannot be withheld from any provider. Sketch a design that still yields a defensible estimate.
How have you applied SQL or SAS to manipulate large-scale healthcare d…
How have you applied SQL or SAS to manipulate large-scale healthcare data?
Approach
- Compute rates by summing numerator and denominator separately, never by averaging rates.
- State the window function and its partition and ordering out loud before writing it.
- Check whether any join is one-to-many before aggregating, or the sums inflate.
Follow-up
- How does the query change if the join becomes one-to-many?
- How would you verify this result without re-running the same query?
Report site activation to first randomization without hiding non-enrollers
study_site holds one row per (study_id, site_id): site_activation_date, which is NULL for a site selected but never activated, and site_status. study_subject_visit holds subject_visit_id, study_id, site_id, subject_id, randomization_ts (NULL for screen failures), visit_name, visit_number, actual_visit_date and visit_status, with one row per subject per protocol visit, so randomization_ts repeats across every visit of a randomized subject and a site that has screened nobody has no rows there at all. For one study_id and a stated data cut date, return per activated site the activation date, the first randomization_ts and the days between them, with activated sites that have randomized nobody still present. Add a study-level summary giving median days to first randomization and the share of activated sites with no randomization by day 90.
Approach
- Take the site universe from study_site, never from study_subject_visit. The visit table can only contain sites that have screened at least one subject, so a universe built from DISTINCT site_id there omits exactly the sites this metric exists to expose. Filter study_site to the study and to site_activation_date IS NOT NULL, then LEFT JOIN the per-site first randomization.
- Collapse the grain before aggregating anything on the visit side. The table repeats randomization_ts across every visit of a randomized subject, so any count taken at row grain is inflated by visits per subject. MIN(randomization_ts) per site is safe, COUNT is not.
- State the date boundary rule. randomization_ts is a timestamp and site_activation_date is a date, so a randomization at 23:40 local time can land on either side of a day boundary depending on the zone the timestamp is stored in. Cast once, deliberately, and say which zone.
- Use PERCENTILE_CONT(0.5) WITHIN GROUP (ORDER BY days) for the median and be explicit that it ignores NULLs, so it is a median over enrolling sites only. That is exactly why the non-enroller share is reported beside it rather than instead of it.
- Censor the day-90 denominator against the data cut. A site activated 40 days before the cut has not had 90 days to randomize, so it cannot be scored on that bar and belongs outside that denominator.
Worked solution 25 min
- CTE sites: site_id and site_activation_date from study_site for the study where site_activation_date IS NOT NULL. The (study_id, site_id) key already gives one activation date per site, so assert that key rather than de-duplicating defensively.
- CTE first_rand: site_id and MIN(randomization_ts) over study_subject_visit rows for the study where randomization_ts IS NOT NULL, grouped by site_id.
- LEFT JOIN sites to first_rand and compute days_to_first_randomization with an explicit cast of the timestamp to a date.
- Summary: PERCENTILE_CONT(0.5) over non-null days, plus the count and share of sites with no randomization by day 90, restricted to sites activated at least 90 days before the data cut.
- Compare the site-level row count with COUNT(DISTINCT site_id) in study_subject_visit for the study; the difference is the activated sites that have screened nobody, which is the population the metric is for.
Follow-up
- The same site_id appears under two studies. What breaks, and what is the correct grain for this metric?
- Would you present this as a median, as a Kaplan-Meier curve of time to first randomization, or both, and what does the curve show that the median cannot?
- A site randomized one subject who withdrew at visit 2. Does that site count as enrolling here, and how does that differ from a randomized-and-retained measure?
How do you ensure your analysis is reproducible and meets clinical com…
How do you ensure your analysis is reproducible and meets clinical compliance standards?
Approach
- Fix the population and the time window before naming any metric.
- Restate the decision this analysis has to support, and who acts on the answer.
- Name one primary metric, then the guardrail that stops it being gamed.
Follow-up
- What would you do if the primary metric and the guardrail moved in opposite directions?
- How would you detect that the metric is being gamed rather than genuinely improving?
How do you approach causal inference in observational studies?
How do you approach causal inference in observational studies?
Approach
- State what result would change your recommendation, so the answer is falsifiable.
- Restate the decision this analysis has to support, and who acts on the answer.
- Name one primary metric, then the guardrail that stops it being gamed.
Follow-up
- What would you do if the primary metric and the guardrail moved in opposite directions?
- How would you detect that the metric is being gamed rather than genuinely improving?
Can you provide an example of how you prioritized multiple competing p…
Can you provide an example of how you prioritized multiple competing projects?
Approach
- Restate the decision this analysis has to support, and who acts on the answer.
- Name one primary metric, then the guardrail that stops it being gamed.
- Decompose the metric into the rates that drive it, and say which one you would check first.
Follow-up
- Which segment would you cut first, and what would that rule out?
- What would you do if the primary metric and the guardrail moved in opposite directions?
Walk me through how you would approach a new analytics project from th…
Walk me through how you would approach a new analytics project from the initial data exploration phase to deployment.
Approach
- Name one primary metric, then the guardrail that stops it being gamed.
- State what result would change your recommendation, so the answer is falsifiable.
- Decompose the metric into the rates that drive it, and say which one you would check first.
Follow-up
- How would you detect that the metric is being gamed rather than genuinely improving?
- Which segment would you cut first, and what would that rule out?
Evaluate a book-wide benefit change with no untreated members
On 1 January a therapeutic class moves from formulary tier 2 to tier 3, raising member cost share, for the entire commercial group book at once. No untreated subset of that book exists. You have 36 months of pharmacy_claim and member_enrollment covering that book plus the Medicare Advantage and Medicaid managed books, which are unaffected. Outcomes are class fills per 1,000 member-months and the share of members with PDC at or above 0.80. Give the design, the identifying assumption, and how you would test it.
Approach
- Rule out the single-series interrupted time series first and say why. The change lands on 1 January, which is also when deductibles reset, benefit designs change, and members switch plans, so a level shift at the new year is confounded with the entire annual benefit cycle. Any design that cannot separate those two is not usable here.
- Build an event-study difference-in-differences with the unaffected product books as controls, estimating month-by-month coefficients relative to December. The lead coefficients are the test of the identifying assumption, not decoration: they should be indistinguishable from zero, and you should say in advance what magnitude of lead violation would make you abandon the design.
- State what the control books are doing for you and what they are not. They experience the same January reset, which is precisely why they are useful, but they differ in population age, cost-sharing structure, and eligibility churn, so parallel counterfactual trends is a real assumption and residual confounding should be named rather than waved at.
- Add a synthetic control as the robustness check: construct a weighted combination of donor series (other product books crossed with other therapeutic classes) that tracks the treated series through the pre-period, and do inference by permutation, assigning the intervention to each donor and comparing post-to-pre RMSPE ratios. Require that the treated pre-period sits inside the convex hull of the donors, and abandon the approach if pre-period fit is poor.
- Fix the population before estimating anything. If the tier move pushes members out of the book, the post-period population differs from the pre-period one, so restrict to members continuously enrolled across the window with a stated allowable gap, and report sensitivity to that gap. Note that pharmacy claims adjudicate in days, so unlike a medical-cost series this outcome is essentially complete within weeks.
Worked solution 45 min
- Build a monthly panel of fills per 1,000 member-months and PDC share by product book, restricted to members continuously enrolled across the window with a 45-day allowable gap.
- Plot the treated and control series for 24 pre-period months and inspect visually before fitting anything.
- Estimate an event-study DiD with month-relative-to-January coefficients, product fixed effects, and calendar-month fixed effects, clustering standard errors at the product-book level or higher.
- Run the placebo: re-estimate as if the change happened on the prior 1 January, which isolates the annual reset from the tier move.
- Fit a synthetic control on donor product-class series, check pre-period RMSPE, and run the permutation inference across donors.
Follow-up
- The lead coefficients are not flat: the treated book was already drifting down for six months. What do you do without abandoning the question?
- Therapeutic substitution is expected. How do you tell a true reduction in therapy from members moving to a cheaper drug in the same class?
- How would you report the result so a clinical committee can act on it, given that fills per 1,000 member-months is not an outcome anyone treats?
Readmission rate rose while every facility improved
Quarter over quarter the 30-day unplanned readmission rate for an attributed population rose from 14.2 to 15.1 percent, yet all eleven facilities in encounter show a flat or falling rate over the same period. You have encounter (facility_id, admit_ts, discharge_ts, encounter_type, admission_type, discharge_disposition, drg_code, is_planned_admission, index_encounter_id) and twelve months of prior medical_claim_line for comorbidities. Explain the direction reversal numerically, and state what the population-level number should be reported as instead.
Approach
- Confirm the reversal is arithmetic, not a definition difference, by recomputing both the facility rates and the pooled rate from the same query with the same index-stay exclusions.
- Decompose the pooled change exactly with a Kitagawa split. With facility weights w and within-facility rates r, the change equals the sum over facilities of (w_1 - w_0) times (r_0 + r_1)/2, the mix term, plus the sum of (w_0 + w_1)/2 times (r_1 - r_0), the within term. If the mix term exceeds the total change and the within term is negative, the reversal is volume shifting toward facilities with higher baseline rates.
- Ask why the weights moved. Check index-stay volume by facility, and check whether an exclusion changed behaviour: acute-to-acute transfers (discharge_disposition 'transfer_acute') must not open an index stay, and if one facility began transferring more, its denominator shrinks toward its sickest retained patients.
- Check case mix inside the facilities too, using drg_code and comorbidities drawn from the 12 months of claims before admit_ts, excluding complications of the index stay itself. A facility rate can be flat while its case mix worsens.
- Replace the raw pooled rate with an observed over expected ratio, where expected is the sum of predicted probabilities from a model fitted on age, sex and prior comorbidities. Raw rates are not comparable across a population whose facility and case mix is moving.
Follow-up
- Your O/E ratio is 1.04 with a 95 percent interval of 0.96 to 1.13. What does that let you say to a facility, and what does it not?
- If one facility contributes 40 percent of index stays, how does that change how you present the decomposition?
- How would you handle a member with two index stays in the quarter, where the second is also a readmission from the first?
For a candidate whose interviews will centre on A/B testing, metric movement and causal claims. Design comes before arithmetic, arithmetic before analysis, and the week ends by rehearsing the readout rather than the derivation.
Prepare, practise & reflect
One practical outcome each day. Spend longer where you need it.
0 / 7 done01Design one test end to end on paper
- Take a single feature change and write the full design: randomization unit, the exact point of exposure, the primary metric with its grain, guardrails, allocation, planned duration, and the decision rule committed before any data exists.
- Write why the randomization unit must sit at or above the level where treatment can spill over, and give one case where user-level randomization is still contaminated (shared accounts or devices, or two participants in the same marketplace).
- State in advance what you will do if the primary metric is flat while a secondary metric is significant.
Deliverable: A one-page test design with a decision rule written before launch.
Practice prompt ↗Practice prompt ↗Worked solution ↗02Power arithmetic until it is automatic
- Compute required sample size per arm for a binary metric with the normal approximation, n is approximately 2 times (z for alpha/2 plus z for power) squared times p(1 minus p) divided by delta squared, for baselines of 2, 10 and 40 percent at a 5 percent relative lift, and note that for a fixed relative lift the requirement falls as the baseline rises because delta grows proportionally with p.
- Redo the calculation for a continuous metric using variance in place of p(1 minus p), and show why a heavy-tailed quantity such as revenue per user needs either far more traffic or a capped version with a stated cap.
- Convert one of the results into weeks given a weekly eligible traffic figure, then list the two honest ways to shorten it (accept a larger detectable effect, or reduce variance) and write why quietly lowering the power target is a decision to miss more real wins, not a speedup.
Deliverable: A small script or sheet that maps baseline, minimum detectable effect, alpha and power to sample size and weeks, cross-checked against a published calculator.
Practice prompt ↗Practice prompt ↗03Variance and the unit-of-analysis problem
- Take a ratio metric whose denominator is not the randomization unit (clicks per session, randomized by user) and compute the standard error twice, once naively at session level and once by the delta method or a user-level bootstrap, then record how much the naive version understates it.
- Implement CUPED on simulated data: choose a pre-period covariate X measured before assignment, estimate theta as Cov(Y, X) divided by Var(X), and analyse Y minus theta times (X minus its mean) in place of Y. Confirm the variance of the adjusted outcome equals the raw variance multiplied by one minus the squared correlation between Y and X, so a correlation of 0.45 removes about 20 percent of the variance and not 80.
- Now run that simulation a few hundred times and confirm the adjusted effect estimate is unbiased for the same effect rather than numerically identical to the raw one. Within any single run the two differ, sometimes by a large fraction of the true effect, because the two arms' pre-period covariate means never coincide exactly in a finite sample; they agree in expectation, which is the property that matters and the one to state out loud.
Deliverable: A notebook showing the adjusted estimator with a measurably smaller variance than the raw one, plus a repeated-simulation table showing the two estimators agreeing on average while differing run by run.
Practice prompt ↗Practice prompt ↗04Validity threats you can actually test for
- Run a sample ratio mismatch check as a chi-square goodness-of-fit test against the intended allocation, and write the three causes you would chase first (assignment logged before exposure, an arm-specific redirect or load failure, bot filtering applied asymmetrically).
- Simulate peeking: generate A/A data, test daily at alpha 0.05 across 14 looks, record the inflated false positive rate, then apply an alpha-spending boundary or commit to a fixed horizon and confirm the rate returns to nominal.
- Write how you would separate a novelty effect from a durable lift using the treatment effect plotted against days since first exposure, and what shape would change your recommendation.
Deliverable: One table showing the peeking false positive rate before and after correction, plus a written SRM triage list.
Practice prompt ↗Practice prompt ↗Worked solution ↗05When randomization is not available
- Write the identifying assumption for difference-in-differences (parallel trends in the absence of treatment), then plot pre-period trends for two candidate control groups and justify rejecting one of them.
- Design a switchback test for a change where user-level randomization would leak across participants, choosing a time-block length against the carryover you expect and saying how you would detect carryover in the data.
- List what an interrupted time series or a synthetic control buys you and the one thing neither can rule out: an unobserved shock that coincides with the launch.
Deliverable: A one-page memo recommending a single quasi-experimental design and naming its weakest assumption explicitly.
Practice prompt ↗Practice prompt ↗06The readout query
- Write the assignment-to-exposure join that returns exactly one row per unit per experiment, and handle units appearing in both arms by excluding and counting them rather than silently keeping one.
- Compute the per-arm metric, its variance and the relative lift with a confidence interval in SQL, then reproduce the identical numbers in a notebook as a cross-check.
- Add a segment breakdown and write the sentence that keeps it from being p-hacking: segments declared in advance, everything else reported as exploratory and corrected for multiplicity.
Deliverable: A single query that outputs the full readout table, matched to a notebook recomputation.
Practice prompt ↗Practice prompt ↗07Present it to someone who will not read the appendix
- Give a 10-minute readout of a real or simulated experiment in the order decision, number, uncertainty, caveat.
- Have your listener ask "can we ship it" in the case where the primary is flat and a guardrail moved, and answer with a recommendation rather than a request for more data.
- Rewrite your opening line so the recommendation lands before any methodology.
Deliverable: A one-page readout whose first line is the recommendation.
Practice prompt ↗Practice prompt ↗Worked solution ↗Expand any day for tasks and deliverables. Your progress is saved on this device.
Data people depend on systems owned by other teams, and much of the job is negotiating for instrumentation, access, or a fix to a broken pipeline. Prepare an example of getting something changed upstream that you did not control. Describe what you asked for, what you traded, and how you worked while you waited.
What is your experience with R or Python in the context of statistical…
What is your experience with R or Python in the context of statistical modeling or clinical data analysis?
Approach
- Name the disagreement or constraint, and how you resolved it with evidence.
- Close with what you would do differently, concretely.
- Pick a story where you drove the decision, not one where you observed it.
Follow-up
- What did you decide not to do, and why?
- How did you know the outcome was caused by your change?
Explain an incomplete cost series to a non-technical executive
An executive opens a dashboard showing risk-adjusted allowed PMPM down 6 percent across the last three incurred months and asks whether the cost initiative is working. You know pharmacy adjudicates within days, professional claims within weeks, and inpatient facility claims over months, so those three months are both undercounted and mix-shifted toward cheap services. There is also a genuine movement of roughly 1.5 percent in the older, complete months. Deliverable: a two-minute spoken answer, the change you make to the chart, and what you commit to telling them and when.
Approach
- The probe is whether you can be honest about uncertainty without sounding evasive. Executives read hedging as not knowing, so the answer has to end in a commitment.
- Separate the two claims immediately. The 6 percent is an artefact of incomplete data, and there is a smaller real movement in the months that are complete. Delivering only the debunk leaves them holding nothing.
- Explain the lag in their terms: the bills for the most expensive care arrive last, so an incomplete month always looks cheap and always looks like it is improving. Keep the phrase completion factor out of the first pass.
- Fix the chart instead of explaining around it. Shade or omit the incomplete months, print the paid-through date on the axis, and overlay the same series as it looked at equivalent maturity a year earlier so the shape is comparable rather than merely lower.
- Close with a date and a magnitude. Commit to a restated figure once runout matures, say roughly how far you expect the 6 percent to shrink, and name what you would need to see to call the initiative working.
Follow-up
- They ask for your best guess today, knowing it is provisional. What do you say?
- The restated number comes back at 1 percent. How do you handle having flagged the 6 percent at all?
- How do you stop this dashboard producing the same conversation next quarter?
Push back on an over-broad extract without blocking the work
A researcher asks for a one-off extract covering 12,000 members: member_id, date of birth, five-digit residential postal code, full lab_result rows including value_text, and clinical note text, held on their laptop for a retrospective analysis of one lab analyte over time. They describe it as de-identified because names are excluded. A flat refusal is not an acceptable answer. Deliverable: the column list you will actually provide with a justification per retained field, the sentence explaining why free text defeats an enumerated-identifier approach, your small-cell rule for the published stratification, and what you deliver this week.
Approach
- The probe is whether privacy is a design skill for you or a compliance reflex. Flat refusal and unquestioned fulfilment both fail, for opposite reasons.
- Reconstruct the analysis from the research question rather than from the request. A longitudinal trend in one analyte needs a stable pseudonymous subject key, the analyte's loinc_code, value_numeric, units, the reference bounds, and a date. It does not need names, notes, or a precise birth date.
- Replace each identifier with the least precise version that still answers the question: a salted per-study pseudonym instead of member_id, age in years or an age band instead of date of birth, a consistent per-subject date offset if only intervals matter, and a coarser geography than five-digit postal code.
- Explain the free-text problem in one sentence. Removing an enumerated list of identifier fields does not de-identify a note, because notes carry names, relationships, employers, dates and rare clinical detail in prose, so only a reviewed extraction into structured fields or a formal statistical determination addresses it.
- Set the publication rule before the analysis runs. Suppress cells below a stated threshold and suppress complements too, because a reader holding a row total and all but one cell recovers the suppressed count by subtraction.
- Keep them moving. Deliver the reduced extract into a controlled environment this week rather than onto a laptop, and offer to derive any note-based variable yourself as a structured flag so they never need the prose.
Follow-up
- They say the age band loses resolution their model needs. What do you do?
- How do you set the suppression threshold, and who signs off on it?
- The analysis later needs linking to a second data source. What changes?
- 01
What is your experience with R or Python in the context of statistical modeling or clinical data analysis?
- 02
An executive opens a dashboard showing risk-adjusted allowed PMPM down 6 percent across the last three incurred months and asks whether the cost initiative is working. You know pharmacy adjudicates within days, professional claims within weeks, and inpatient facility claims over months, so those three months are both undercounted and mix-shifted toward cheap services. There is also a genuine movement of roughly 1.5 percent in the older, complete months. Deliverable: a two-minute spoken answer, the change you make to the chart, and what you commit to telling them and when.
- 03
A researcher asks for a one-off extract covering 12,000 members: member_id, date of birth, five-digit residential postal code, full lab_result rows including value_text, and clinical note text, held on their laptop for a retrospective analysis of one lab analyte over time. They describe it as de-identified because names are excluded. A flat refusal is not an acceptable answer. Deliverable: the column list you will actually provide with a justification per retained field, the sentence explaining why free text defeats an enumerated-identifier approach, your small-cell rule for the published stratification, and what you deliver this week.
Is this an official Pra Health Sciences interview guide?
No. It is PracHub's own research and practice material for the Data Scientist role at Pra Health Sciences. Rounds and questions reflect what candidates have reported, not a process Pra Health Sciences has published, and they change over time. Confirm the current format and scope with your recruiter.
PracHub interview research ↗Is the interview process mostly technical or behavioral?
It is a balanced mix. You should expect to be challenged on your technical knowledge, but your success will often hinge on how well you can explain your work to stakeholders and demonstrate that you are a good cultural fit.
PracHub interview research ↗How much time should I dedicate to preparing for LeetCode-style questions?
While coding skills are tested, the focus at Pra Health Sciences is often more on practical application and domain knowledge than on abstract algorithmic puzzles. Prioritize your understanding of statistics and real-world data handling over high-level competitive programming.
PracHub interview research ↗Are there remote or hybrid options?
Many roles have specific location requirements (e.g., Raleigh, NC or Blue Bell, PA). Always verify the location status for the specific requisition you are applying to, as this may impact your interview focus.
PracHub interview research ↗What is the best way to handle a question about a technology I haven't used?
Be honest about your experience level. Pivot to discussing how your existing knowledge of similar tools allows you to pick up new technologies quickly, and provide examples of times you have successfully learned a new skill on the job.
PracHub interview research ↗Sources & methodology 3 sources ↗
No official company page is cited. Rounds and questions come from candidate reports and PracHub editorial material; each source shows the date it was read.
- 01PracHub interview research ↗
PracHub editorial research into this company and role, maintained with this guide. Candidate-reported, not an employer publication.
PracHub page · Accessed 2026-09-22 - 02PracHub Data Scientist practice ↗
Cross-company practice questions for this role.
PracHub page · Accessed 2026-09-22 - 03PracHub interview preparation framework ↗
The framework the preparation plan follows.
PracHub page · Accessed 2026-09-22
Explore related engineering environments and compare the preparation focus.
Veracyte Data Scientist Interview Questions & Guide 2026
Causal-inference exercises for Veracyte data scientist prep: difference-in-differences, matching, instrumental variables, and knowing when observational data simply cannot answer the question asked.
Zoetis Data Scientist Interview Questions & Guide 2026
Metric-diagnosis practice for Zoetis data scientist candidates: a number moves week over week and you work out why, splitting by segment, ruling out a logging or release change, and separating a mix shift from a real change in user behaviou
Vizient Data Scientist Interview Questions & Guide 2026
Communication practice for Vizient data scientist candidates: turn an analysis into a recommendation, name the uncertainty honestly, and answer the follow-up a skeptical stakeholder will raise.
Vibrant Emotional Health Data Scientist Interview Questions & Guide 2026
Case practice for the Vibrant Emotional Health data scientist interview, where the prompt is deliberately underspecified and your first move is scoping it into something measurable.